Multiple Myeloma: all 3,712 studies

Page 10 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.

• A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT03567616Phase 2Results posted
• A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03548207Phase 1/2Results posted
• To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)CompletedNCT03544281Phase 1/2Results posted
• A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 AntibodyCompletedNCT03525678Phase 2Results posted
• A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology CentersTerminatedNCT03512353Phase 2Results posted
• Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational AnalysisCompletedNCT03506386Results posted
• Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT03506360Phase 2Results posted
• Short Course Daratumumab in Patients With Multiple MyelomaCompletedNCT03490344Phase 2Results posted
• Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMMTerminatedNCT03481556Phase 1/2Results posted
• Daratumumab in Treating Transplant-Eligible Patients With Multiple MyelomaCompletedNCT03477539Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological MalignanciesTerminatedNCT03465540Phase 1Results posted
• Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to ChemotherapyTerminatedNCT03457142Phase 2Results posted
• Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal ImpairmentCompletedNCT03450057Phase 2Results posted
• Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance TreatmentTerminatedNCT03440411Phase 3Results posted
• A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)CompletedNCT03439293Phase 2Results posted
• A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)CompletedNCT03439280Phase 1/2Results posted
• A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and DexamethasoneCompletedNCT03433001Results posted
• Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple MyelomaCompletedNCT03430011Phase 1/2Results posted
• Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell TransplantationCompletedNCT03417284Phase 1/2Results posted
• A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based TherapyCompletedNCT03416374Phase 4Results posted
• A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment RegimensCompletedNCT03412565Phase 2Results posted
• Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on LenalidomideTerminatedNCT03411031Phase 2Results posted
• Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple MyelomaCompletedNCT03398200Phase 2Results posted
• High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT03389347Not applicableResults posted
• Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete RemissionTerminatedNCT03376477Phase 2Results posted
• Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT03361748Phase 2Results posted
• LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple MyelomaCompletedNCT03361306Phase 2Results posted
• A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03357952Phase 2/3Results posted
• Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)TerminatedNCT03340883Phase 1/2Results posted
• Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple MyelomaCompletedNCT03338972Phase 1Results posted
• Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT03333746Phase 2Results posted
• Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood CancerTerminatedNCT03333486Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple MyelomaTerminatedNCT03318861Phase 1Results posted
• Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin LymphomaCompletedNCT03317899Phase 2Results posted
• A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple MyelomaCompletedNCT03312530Phase 1/2Results posted
• Allogeneic Stem Cell Transplantation for Multiple Myeloma and MyelofibrosisTerminatedNCT03303950Phase 2Results posted
• A Study of Daratumumab in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT03290950Phase 2Results posted
• P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)TerminatedNCT03288493Phase 1/2Results posted
• APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple MyelomaTerminatedNCT03287804Phase 1/2Results posted
• A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03277105Phase 3Results posted
• Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma PatientsCompletedNCT03275285Phase 3Results posted
• Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic MalignanciesTerminatedNCT03272633Early Phase 1Results posted
• PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple MyelomaCompletedNCT03269136Phase 1Results posted
• Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT03267888Phase 1/2Results posted
• Comparison of F-18 FDG and C-11 Acetate PET in Multiple MyelomaCompletedNCT03262389Phase 2Results posted
• Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT03256045Phase 2Results posted
• Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell TransplantationTerminatedNCT03246906Phase 2Results posted
• A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)Active, not recruitingNCT03246529Phase 3Results posted
• Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple MyelomaCompletedNCT03224507Phase 2Results posted
• MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple MyelomaTerminatedNCT03218163Phase 2Results posted
• A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple MyelomaTerminatedNCT03215030Phase 1/2Results posted
• Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple MyelomaCompletedNCT03202628Phase 2Results posted
• Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaTerminatedNCT03201250Phase 1/2Results posted
• Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) PatientsCompletedNCT03194867Phase 1/2Results posted
• Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell TransplantActive, not recruitingNCT03192397Phase 1/2Results posted
• Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study)CompletedNCT03188536Results posted
• Bendamustine and Melphalan in MyelomaCompletedNCT03187223Phase 2Results posted
• Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/DexCompletedNCT03180736Phase 3Results posted
• A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple MyelomaCompletedNCT03170882Phase 2Results posted
• NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"CompletedNCT03169361Results posted
• Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple MyelomaTerminatedNCT03168438Phase 1Results posted
• Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical TransplantationCompletedNCT03159702Phase 2Results posted
• Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.CompletedNCT03158688Phase 3Results posted
• A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to LenalidomideTerminatedNCT03151811Phase 3Results posted
• High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell TransplantCompletedNCT03128359Phase 2Results posted
• Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and LenalidomideTerminatedNCT03117361Phase 2Results posted
• Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple MyelomaCompletedNCT03110562Phase 3Results posted
• Evaluating Effectiveness of Powered Drill Bone Marrow BiopsyCompletedNCT03078452Not applicableResults posted
• Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple MyelomaTerminatedNCT03031730Phase 1Results posted
• Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Phase 3Results posted
• Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCTCompletedNCT03018223Phase 1Results posted
• Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT03012880Phase 2Results posted
• A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03000452Phase 2Results posted
• Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme MalignanciesTerminatedNCT02991898Phase 2Results posted
• Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma PatientsCompletedNCT02990338Phase 3Results posted
• Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple MyelomaCompletedNCT02969837Phase 2Results posted
• A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02963493Phase 2Results posted
• Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple MyelomaCompletedNCT02958969Phase 4Results posted
• A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple MyelomaCompletedNCT02951819Phase 2Results posted
• Daratumumab in Treating Patients With Multiple MyelomaCompletedNCT02944565Phase 2Results posted
• Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma PatientsTerminatedNCT02943473Phase 2Results posted
• Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple MyelomaCompletedNCT02939183Phase 1Results posted
• High Dose Carfilzomib for Newly Diagnosed MyelomaCompletedNCT02937571Phase 1/2Results posted
• Study Testing Radium-223 Dichloride in Relapsed Multiple MyelomaTerminatedNCT02928029Phase 1/2Results posted
• Ixazomib Rollover StudyCompletedNCT02924272Phase 2Results posted
• A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin LymphomaCompletedNCT02919670Not applicableResults posted
• A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT02917941Phase 2Results posted
• Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)TerminatedNCT02906332Phase 2Results posted
• A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering MyelomaCompletedNCT02903381Phase 2Results posted
• Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple MyelomaCompletedNCT02902965Phase 2Results posted
• Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell TransplantCompletedNCT02880228Phase 2Results posted
• Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple MyelomaCompletedNCT02874742Phase 2Results posted
• Oral ONC201 in Relapsed/Refractory Multiple MyelomaTerminatedNCT02863991Phase 1/2Results posted
• Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma PatientsCompletedNCT02843074Phase 2Results posted
• Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma PatientsCompletedNCT02812706Phase 1/2Results posted
• A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple MyelomaTerminatedNCT02807454Phase 2Results posted
• CART-19 Post-ASCT for Multiple MyelomaTerminatedNCT02794246Phase 2Results posted
• Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple MyelomaCompletedNCT02780609Phase 1/2Results posted
• A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple MyelomaActive, not recruitingNCT02773030Phase 1/2Results posted
• Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and RecoveryCompletedNCT02767388Results posted

← Multiple Myeloma overview